Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

20091,121 citationsJournal Articlebronze Open Access

Authors

Matthew Smith · Harvard University

Blair Egerdie

Narciso Hernández Toriz · Centro Medico Nacional Siglo XXI

Robert Feldman · Dermatology Specialists

Teuvo L.J. Tammela · Tampere University

Fred Saad · Centre Hospitalier de l’Université de Montréal

Jiří Heráček · Energy and Environmental Consultancy

Abstract

Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. (ClinicalTrials.gov number, NCT00089674.)

Topics & Keywords

Bone health and treatments Prostate Cancer Treatment and Research Bone health and osteoporosis research

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 8, pp. 745-755

DOI: 10.1056/nejmoa0809003

Field-Weighted Citation Impact: 56.70

Command Palette

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details